Membranous nephropathy and carbamazepine

Sangeetha, B; Sandeep, P; Varalaxmi, B; Chaitanya, V; Ram, R; Kumar, V Siva

doi:10.4103/0971-4065.132030

Cited by 6 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oxoketene dithioacetals are useful 3-carbon 1,3-dipolarophiles that have been extensively employed in the literature for the preparation of five-membered, six-membered, and seven-membered heterocyclic rings from its reaction with bidentate nucleophiles such as hydrazine hydrate, hydroxylamine hydrochloride, urea, thiourea, o-phenylenediamine, o-aminophenol, and o-aminothiophenol [18]. Application of this strategy on oxoketene dithioacetal derivatives 6 and 7 with the indicated bidentate nucleophiles gave the pyrazoles (8 and 9), isoxazoles (10 and 11), pyrimidines (12)(13)(14)(15), and azepines (16)(17)(18)(19), respectively, in high yield and purity (Scheme 1). The structure of compounds 6, 7 and 8-19 was established on the basis of their microanalysis results as well as their IR, 1 H NMR and MS spectral data.…”

Section: Resultsmentioning

confidence: 99%

“…The conventional reduction of 5-nitroindazole gave its amine analog (i.e., 5-amniindazole 1) which furnished corresponding diazonium chloride (1a) after diazotization. Application of the Japp-Klingemann reaction on aryldiazonium salts with 2-hydroxymethylene cyclohexanone has been demonstrated in the literature [16] to provide an easy access to the corresponding aryl hydrazones, whose subsequent cyclocondensation in acid under the conditions of Fischer indolization offers a very convenient synthetic entry to the corresponding oxocarbazole derivatives [17]. The use of 3-hydroxymethylene-4piperidone in this synthesis affords the corresponding oxoazacarbazoles [16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Novel Synthetic Protocol for the Heteroannulation of Oxocarbazole and Oxoazacarbazole Derivatives through Corresponding Oxoketene Dithioacetals

Tyagi

Kaur

Singh

et al. 2013

Journal of Heterocyclic Chem

View full text Add to dashboard Cite

An efficient novel strategy for the heteroannulation of 6,7‐dihydropyrazolo[3,4‐b]carbazol‐8(1H,5H,9H)‐one 4 and 5‐N‐benzyl‐6,7‐dihydropyrazolo[3,4‐b]carbazol‐8(1H,9H)‐one 5 has been developed to allow the incorporation of pyrazole, isoxazole, pyrimidine, benzodiazepine, and benzothiazepine rings through their corresponding oxoketene dithioacetal derivatives 6 and 7, respectively.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A Novel Synthetic Protocol for the Heteroannulation of Oxocarbazole and Oxoazacarbazole Derivatives through Corresponding Oxoketene Dithioacetals

Tyagi

Kaur

Singh

et al. 2013

Journal of Heterocyclic Chem

View full text Add to dashboard Cite

show abstract

“…Furthermore, the IgG deposited in the GBM could not be confirmed as being related to agalsidase-β or carbamazepine, but there are 2 prior reports of MN being induced during carbamazepine treatment. In both cases, the proteinuria was negative after reducing the carbamazepine dose [9,10] . On the other hand, there has been no report of agalsidase-β causing MN and it is difficult to reduce the amount of enzyme replacement because several reports have shown that this can cause renal damage [5,11] …”

Section: Discussionmentioning

confidence: 99%

“…In both cases, the proteinuria was negative after reducing the carbamazepine dose. [9,10] On the other hand, there has been no report of agalsidase-b causing MN and it is difficult to reduce the amount of enzyme replacement because several reports have shown that this can cause renal damage. [5,11] Therefore, it is important for physicians to know that proteinuria was resolved after reducing the carbamazepine dose in MN during ERT with agalsidase-b and carbamazepine for Fabry disease.…”

Section: Discussionmentioning

confidence: 99%

Membranous nephropathy without vacuolated podocytes in Fabry disease treated with agalsidase-β and carbamazepine

Kanai¹,

Ito²,

Aoyagi³

et al. 2022

Medicine

View full text Add to dashboard Cite

Rationale: Vacuolated podocytes are the most common form of renal damage in Fabry disease, but other types of renal damage have been reported, such as membranous nephropathy (MN) or IgM nephropathy. Enzyme replacement therapy (ERT) is effective at preventing renal damage, but the nephropathies require appropriate treatment to prevent renal damage.Patient concerns: A 22-year-old male with Fabry disease presented with proteinuria during ERT with agalsidase-b and carbamazepine. He had received the treatment for 10 years and maintained normal plasma globotryaosylceramide levels.Diagnosis: Renal biopsy revealed MN without vacuolated podocytes. Immunofluorescent staining of the IgG subclass revealed granular patterns of IgG1, G2, G4, and C3 deposition in the glomerular basement membrane.Interventions: The carbamazepine dose was reduced from 600 mg/day to 200 mg/day (serum concentration 10.0-11.0-4.0-5.0 mg/mL).Outcomes: After reducing the carbamazepine dose, proteinuria was negative, and the patient has had a normal urinalysis for 17 months. Plasma globotryaosylceramide levels have also remained normal.Lessons: This report is a reminder of the co-existence of MN without vacuolated podocytes in Fabry disease during ERT with agalsidase-b and carbamazepine.Physicians should be aware of this form of renal damage in Fabry disease, even during treatment.Abbreviations: ERT = enzyme replacement therapy, GBM = glomerular basement membrane, GL-3 = globotryaosylceramide, UP/UCr = urinary protein/urinary creatinine.

show abstract

“…[ 5 6 ] The major groups of diseases that underlie membranous nephropathy are infections (hepatitis B, hepatitis C, malaria, and schistosomiasis),[ 7 8 ] autoimmune diseases (SLE, rheumatoid arthritis),[ 9 ] malignancies,[ 10 ] and drugs (captopril, penicillamine, gold, carbamazepine etc.,). [ 11 ] Various other unusual associations with membranous nephropathy have also been reported in literature. [ 12 13 ]…”

Section: Discussionmentioning

confidence: 99%

Membranous nephropathy in a patient with charcot-marie-tooth disease: Association of myelin mutations

2018

View full text Add to dashboard Cite

A 40-year-old female presented to the neurologist with gradually progressive weakness of distal and proximal muscles of both lower limbs and cramps for 2 years. She gave a history of similar illness in her paternal grandmother and her father. Her examination revealed bilateral foot drop and mild proximal muscle weakness. She was diagnosed to have peripheral neuropathy and subsequently treated conservatively. Over the next year, she noticed progressive swelling of both lower limb and frothy urine. A nephrology consultation was obtained, and a renal biopsy was done, which showed membranous nephropathy. She was started on steroids and subsequently on tacrolimus as the proteinuria progressively worsened. Her anti-phospholipase A2 receptor antibody was negative both in blood and in the kidney biopsy tissue. A search for a genetic basis of this rare clinical condition was made, and heterozygous mutation was detected in the myelin gene. This mutation was confirmed with genetic sequencing. The mutation is associated with MPZ gene and is associated with multiple hereditary sensorimotor neuropathy. MPZ knockout mice have been shown to have increased glomerular permeability and proteinuria.

show abstract

Membranous nephropathy and carbamazepine

Cited by 6 publications

References 4 publications

A Novel Synthetic Protocol for the Heteroannulation of Oxocarbazole and Oxoazacarbazole Derivatives through Corresponding Oxoketene Dithioacetals

A Novel Synthetic Protocol for the Heteroannulation of Oxocarbazole and Oxoazacarbazole Derivatives through Corresponding Oxoketene Dithioacetals

Membranous nephropathy without vacuolated podocytes in Fabry disease treated with agalsidase-β and carbamazepine

Membranous nephropathy in a patient with charcot-marie-tooth disease: Association of myelin mutations

Contact Info

Product

Resources

About